KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Operating Leases (2019 - 2025)

Exact Sciences (EXAS) has disclosed Operating Leases for 7 consecutive years, with $195.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 5.97% to $195.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $195.5 million through Dec 2025, up 5.97% year-over-year, with the annual reading at $195.5 million for FY2025, 5.97% up from the prior year.
  • Operating Leases for Q4 2025 was $195.5 million at Exact Sciences, up from $163.9 million in the prior quarter.
  • The five-year high for Operating Leases was $211.7 million in Q3 2022, with the low at $157.4 million in Q1 2021.
  • Average Operating Leases over 5 years is $176.6 million, with a median of $171.8 million recorded in 2023.
  • The sharpest move saw Operating Leases soared 50.43% in 2021, then decreased 18.16% in 2024.
  • Over 5 years, Operating Leases stood at $182.2 million in 2021, then grew by 0.13% to $182.4 million in 2022, then grew by 4.39% to $190.4 million in 2023, then fell by 3.1% to $184.5 million in 2024, then grew by 5.97% to $195.5 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $195.5 million, $163.9 million, and $166.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.